In this emergency episode of Hims House, the crew covers the FDA's surprise resolution of the semaglutide shortage. They discuss its immediate market impact, including significant stock price movements. Bayside provides a detailed analysis of the implications for short-term and long-term traders. The conversation then shifts to HIMS' two recent acquisitions—a peptide manufacturing facility and an at-home testing lab—and their effects on the company's future. As they wrap up, the team outlines critical points to watch in the upcoming earnings report, especially guidance for 2025 and strategic plans for patient care in light of the new developments.
00:00 Semiglutide Shortage Resolved According to FDA
01:33 Short-term vs Long-term Investment Perspectives
04:05 Institutional Ownership and Long-term Implications
04:48 Future Projections and Speculations
06:01 FDA Policies and GLP-1 Sales Impact
22:02 Acquisitions and Strategic Moves
32:00 Earnings Expectations and Guidance
42:18 Conclusion
Get full access to Hims House at
himshouse.substack.com/subscribe
